Kwangdong to introduce new rheumatoid arthritis treatment

Published: 2008-12-24 06:45:00
Updated: 2008-12-24 06:45:00
Kwangdong Pharm has announced that it has signed an exclusive license agreement with Israel based Can-Fite BioPharma Ltd. to develop and commercialize the drug CF101 for the treatment of rheumatoid arthritis in Korea.

kwangdong plans to launch CF101 in 2013 after completion of local clinical ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.